EICHORCondition: Vitiligo · Sponsor: AbbVie
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo (NSV). Adverse effects and change in disease activity will be assessed. Upadacitinib is currently being investigated for the treatment of NSV. There will be 2 replicate studies running at the same time (Study 1 and Study 2 with periods A and B), an optional exploratory NB-UVB phototherapy study (Study 3), and a re-randomized dose-escalation study (Study 4). In Period A, participants are placed in 1 of 2 groups called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will receive placebo. In Period B, all participants will receive upadacitinib. Approximately 540 adult and adolescent participants with NSV will be enrolled between each main study at around 180 sites worldwide with an option for adult participants who completed Period A of either study and did not achieve T-VASI90 at week 48 while on study drug, to enter Study 3. Participants who failed to achieve T-VASI75 response at week 118 of Study 1 or 2 or at week 70 of Study 3 will be considered for entry into Study 4. In Studies 1 and 2: Period A, participants will receive oral tablets of upadacitinib or placebo once a day for 48 weeks. In Period B, participants will receive oral tablets of upadacitinib 15 mg once a day for 112 wee…
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Advanced Research Associates - Glendale /ID# 259915 | Glendale, Arizona, United States | — |
| Alliance Dermatology and Mohs Center /ID# 259926 | Phoenix, Arizona, United States | — |
| Private Practice - Dr. Tooraj Raoof /ID# 260055 | Encino, California, United States | — |
| University of California Irvine /ID# 260080 | Irvine, California, United States | — |
| Vitiligo & Pigmentation Institute of Southern California /ID# 259970 | Los Angeles, California, United States | — |
| Dermatology Research Associates /ID# 260056 | Los Angeles, California, United States | — |
| Duplicate_Stanford University /ID# 260081 | Redwood City, California, United States | — |
| Integrative Skin Science and Research /ID# 260060 | Sacramento, California, United States | — |
| University of California Davis Health /ID# 260062 | Sacramento, California, United States | — |
| Clinical Trials Research Institute /ID# 259910 | Thousand Oaks, California, United States | — |
| Skin Care Research Boca Raton /ID# 260094 | Boca Raton, Florida, United States | — |
| Apex Clinical Trials /ID# 260096 | Brandon, Florida, United States | — |
+ 136 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06118411